Compare · ELOX vs ZYME
ELOX vs ZYME
Side-by-side comparison of Eloxx Pharmaceuticals Inc. (ELOX) and Zymeworks Inc. (ZYME): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ELOX focuses on Biotechnology: Biological Products (No Diagnostic Substances), while ZYME focuses on Biotechnology: Pharmaceutical Preparations.
- ZYME is the larger of the two at $393.4M, about 5.1x ELOX ($77.9M).
- ZYME has been more active in the news (6 items in the past 4 weeks vs 3 for ELOX).
- ZYME has more recent analyst coverage (25 ratings vs 5 for ELOX).
- Company
- Eloxx Pharmaceuticals Inc.
- Zymeworks Inc.
- Price
- -
- -
- Market cap
- $77.9M
- $393.4M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 3
- 6
- Recent ratings
- 5
- 25
Eloxx Pharmaceuticals Inc.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Zymeworks Inc.
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Latest ELOX
- Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
- SEC Form 8-K filed by Eloxx Pharmaceuticals Inc.
- SEC Form 10-Q filed by Eloxx Pharmaceuticals Inc.
- Guggenheim initiated coverage on Eloxx Pharmaceuticals with a new price target
- Large owner Domicilium Real Estate Fund Iii Lp acquired 600,000 shares (SEC Form 4)
- New insider Domicilium Real Estate Fund Iii Lp claimed ownership of 14,285 shares (SEC Form 3)
- SEC Form 4 filed by Director Kjellson Nina S
- SEC Form 4 filed by Director Webster Stephen W
- SEC Form 4 filed by Director Walts Alan Edmund
- SEC Form 4 filed by Director Rubin Steven D
Latest ZYME
- Zymeworks Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
- Zymeworks Announces Participation in Upcoming Investor Conferences
- SEC Form 10-Q filed by Zymeworks Inc.
- Zymeworks Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results
- Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
- EVP & Chief Operating Officer Hollywood Mark was granted 939 shares, increasing direct ownership by 0.71% to 133,852 units (SEC Form 4)
- A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs
- Zymeworks Inc. filed SEC Form 8-K: Regulation FD Disclosure